Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics

Hybridoma

Volumn 31, Issue 2, 2012, Pages 77-86

  Kuo, Shu Ru ^a   Tahir, Salahaldin A ^b   Park, Sanghee ^b   Thompson, Timothy C ^b   Coffield, Scott ^a   Frankel, Arthur E ^a   Liu, Jen Sing ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAVEOLIN 1; CAVEOLIN 1 ANTIBODY; GLUTATHIONE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYBRIDOMA CELL CULTURE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; SCREENING TEST; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CAVEOLIN 1; CELL LINE, TUMOR; HUMANS; HYBRIDOMAS; MALE; MICE; MICE, KNOCKOUT; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS;

ANIMALIA; MUS;

EID: 84859969455     PISSN: 15540014     EISSN: 15578348     Source Type: Journal    
DOI: 10.1089/hyb.2011.0100     Document Type: Article

References (42)

1. Schlegel A, Volonte D, Engelman JA, Galbiati F, Mehta P, Zhang XL, Scherer PE, and Lisanti MP: Crowded little caves: structure and function of caveolae. Cell Signal 1998;10:457-463. (Pubitemid 28404429)
2. Schlegel, A, Pestell RG, and Lisanti MP: Caveolins in cholesterol trafficking and signal transduction: Implications for human disease. Front Biosci 2000;5:D929-937.
3. Williams TM, and Lisanti MP: The caveolin proteins. Genome Biol 2004;5:214.
4. Okamoto T, Schlegel A, Scherer PE, and Lisanti MP: Caveolins, a family of scaffolding proteins for organizing preassembled signaling complexes' at the plasma membrane. J Biol Chem 1998;273:5419-5422. (Pubitemid 28123999)
5. Razani B, Schlegel A, Liu J, and Lisanti MP: Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans 2001; 29:494-499. (Pubitemid 32783645)
6. Shatz M, and Liscovitch M: Caveolin-1: A tumor-promoting role in human cancer. Int J Radiat Biol 2008;84:177-189. (Pubitemid 351323417)
7. Mathew R: Cell-specific dual role of caveolin-1 in pulmonary hypertension. Pulm Med 2011;2011:573432.
8. Liu P, Rudick M, and Anderson RG: Multiple functions of caveolin-1. J Biol Chem 2002;277:41295-41298. (Pubitemid 35257426)
9. Corn PG, and Thompson TC: Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Res 2010;2:111-122.
10. Mouraviev V, Li L, Tahir SA, Yang G, Timme TM, Goltsov A, Ren C, Satoh T, Wheeler TM, Ittmann MM, Miles BJ, Amato RJ, Kadmon D, and Thompson TC: The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 2002;168:1589-1596. (Pubitemid 35034195)
11. Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, Timme TL, Baba S, and Thompson TC: Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 2003;97:1225-1233. (Pubitemid 36237308)
12. Yang G, Timme TL, Frolov A, Wheeler TM, and Thompson TC: Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 2005;103:1186-1194. (Pubitemid 40328089)
13. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, and Park S: The role of caveolin-1 in prostate cancer: Clinical implications. Prostate Cancer Prostatic Dis 2010;13:6-11.
14. Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, and Stanford JL: Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 2010;70: 1020-1035.
15. Thompson TC, Timme TL, Li L, and Goltsov A: Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 1999;4:233-237. (Pubitemid 29424486)
16. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, and Thompson TC: Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001;61:4386-4392. (Pubitemid 32685764)
17. Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D, and Thompson TC: Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol 2007;38:1688-1695. (Pubitemid 47589092)
18. Li L, Ren CH, Tahir SA, Ren C, and Thompson TC: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003;23:9389-9404. (Pubitemid 37499824)
19. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, and Thompson TC: Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000;19: 3256-3265. (Pubitemid 30487412)
20. Li L, Ren C, Yang G, Goltsov AA, Tabata K, and Thompson TC: Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 2009;7:1781-1791.
21. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, and Thompson TC: The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005;8:108-118. (Pubitemid 43118073)
22. Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Zeev A, Pestell RG, and Lisanti MP: Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting betacatenin to caveolae membrane domains. J Biol Chem 2000;275:23368-23377. (Pubitemid 30646240)
23. Yang G, Timme TL, Naruishi K, Fujita T, Fattah el MA, Cao G, Rajagopalan K, Troung LD, and Thompson TC: Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol 2008;84:131-140.
24. Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, Fattah EA, Rajagopalan K, Timme TL, Park S, Kurosaka S, Edamura K, Tanimoto R, Demayo FJ, Goltsov AA, and Thompson TC: Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res 2009;7:1446-1455.
25. Yang G, Park S, Cao G, Goltsov A, Ren C, Truong LD, Demayo F, and Thompson TC: MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol 2010;89:9-19.
26. Bryant KG, Camacho J, Jasmin JF, Wang C, Addya S, Casimiro MC, Fortina P, Balasubramaniam S, Knudsen KE, Schwarting R, Lisanti MP, and Mercier I: Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. Int J Biochem Cell Biol 2011;43:1318-1329.
27. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, Fattah el MA, Kadmon D, and Thompson TC: Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008;68:731-739. (Pubitemid 351206749)
28. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, and Thompson TC: Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001;61:3882-3885. (Pubitemid 32720945)
29. Tahir SA, Park S, and Thompson TC: Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther 2009;8:2286-2296.
30. Liu P, Li WP, Machleidt T, and Anderson RG: Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat Cell Biol 1999;1:369-375. (Pubitemid 129493580)
31. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, Frolov A, Ayala G, Wheeler TM, and Thompson TC: Development of an immunoassay for serum caveolin-1: A novel biomarker for prostate cancer. Clin Cancer Res 2003;9:3653-3659. (Pubitemid 37169231)
32. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, and Kadmon D: Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 2006;12:4872-4875. (Pubitemid 44338573)
33. Ayala GE, Dai H, Tahir SA, Li R, Timme T, Ittmann M, Frolov A, Wheeler TM, Rowley D, and Thompson TC: Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res 2006;66:5159-5164. (Pubitemid 43844938)
34. Siddiqui MR, Komarova YA, Vogel SM, Gao X, Bonini MG, Rajasingh J, Zhao YY, Brovkovych V, and Malik AB: Caveolin-1-eNOS signaling promotes p190RhoGAP-A nitration and endothelial permeability. J Cell Biol 2011;193: 841-850.
35. Scherer PE, Tang Z, Chun M, Sargiacomo M, Lodish HF, and Lisanti MP: Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe. J Biol Chem 1995;270:16395-16401.
36. Fujimoto T, Kogo H, Nomura R, and Une T: Isoforms of caveolin-1 and caveolar structure. J Cell Sci 2000;113:3509-3517.
37. Goetz JG, Minguet S, Navarro-Lerida I, Lazcano JJ, Samaniego R, Calvo E, Tello M, Osteso-Ibanez T, Pellinen T, Echarri A, Cerezo A, Klein-Szanto AJ, Garcia R, Keely PJ, Sanchez-Mateos P, Cukierman E, and Del Pozo MA: Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011;146:148-163.
38. Schmitz M, Zerr I, and Althaus HH: Effect of Cavtratin, a Caveolin-1 scaffolding domain peptide, on oligodendroglial signaling cascades. Cell Mol Neurobiol 20113;1:991-997.
39. Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S, Visconti RP, Zhang J, Hatfield CM, Silver RM, and Hoffman S: Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: Reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Repair 2011;4:15.
40. Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE, Kreitman RJ, and Frankel AE: Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Exp Purif 2004;33:123-133. (Pubitemid 38069820)
41. Kuo SR, Alfano R, Frankel A, and Liu JS: Antibody internalization after cell surface antigen binding is critical for immunotoxin development. Bioconj Chem 2009;20:1975-1982.
42. Kabat E.A. Wu TT, Perry HM, Gottesman KS, and Foeller C: Sequences of Proteins of Immunological Interest. US Department of Health and Human Services, NIH publication no. 91-3240, 1991.